Screener
Danaher DHR Life Sciences — Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Danaher in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Danaher’s 10-Q, filed July 21, 2026.
- Filed
- Jul 20, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000313616-26-000161
| For the Three-Month Period Ended June 26, 2026: | Biotechnology / For the Three-Month Period Ended June 26, 2026: | Life Sciences | Diagnostics | Total |
|---|---|---|---|---|
| Western Europe | 689 | 421 | 430 | 1,540 |
| Other developed markets(b) | 74 | 126 | 93 | 293 |
| High-growth markets(c) | 574 | 573 | 811 | 1,958 |
| Total | $1,920 | $1,879 | $2,466 | $6,265 |
| Revenue type: | ||||
| Recurring | $1,722 | $1,268 | $2,210 | $5,200 |
| Nonrecurring | 198 | 611 | 256 | 1,065 |
| Total | $1,920 | $1,879 | $2,466 | $6,265 |
Item 1. Financial Statements
FAQ
- What is Danaher's life sciences — sales?
- Danaher (DHR) reported life sciences — sales of $1.88B in Q2 2026.
- How has Danaher's life sciences — sales changed year-over-year?
- Danaher's life sciences — sales increased by 5.7% year-over-year, from $1.78B to $1.88B.
- What is the long-term trend for Danaher's life sciences — sales?
- Over 2 years (2023 to 2025), Danaher's life sciences — sales has grown at a 1.3% compound annual growth rate (CAGR), from $7.14B to $7.33B.
- What does life sciences — sales mean?
- Represents the total revenue generated from the sale of goods and services within the Life Sciences business segment. This metric reflects the market demand for scientific instruments, consumables, and related solutions provided to research and clinical customers. It serves as a primary indicator of the segment's top-line growth and market penetration.
Ask your AI about Danaher's life sciences — sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude